{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:14:22Z","timestamp":1778282062710,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T00:00:00Z","timestamp":1519948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological Sciences"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.jphs.2018.03.001","type":"journal-article","created":{"date-parts":[[2018,3,6]],"date-time":"2018-03-06T18:40:44Z","timestamp":1520361644000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice"],"prefix":"10.1016","volume":"137","author":[{"given":"Yuma","family":"Ito","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimichi","family":"Shoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Kitao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Hinoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Shirahase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jphs.2018.03.001_bib1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/157016111795495558","article-title":"Effects of insulin on the vasculature","volume":"9","author":"Breen","year":"2011","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jphs.2018.03.001_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.diabres.2012.09.001","article-title":"Outcomes and lessons from the PROactive study","volume":"98","author":"Scheen","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jphs.2018.03.001_bib3","doi-asserted-by":"crossref","first-page":"7614270","DOI":"10.1155\/2016\/7614270","article-title":"Current advances in the biochemical and physiological aspects of the treatment of type 2 diabetes mellitus with thiazolidinediones","volume":"2016","author":"Alem\u00e1n-Gonz\u00e1lez-Duhart","year":"2016","journal-title":"PPAR Res"},{"key":"10.1016\/j.jphs.2018.03.001_bib4","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1254\/jphs.13236FP","article-title":"Insulin sensitization by a novel partial peroxisome proliferator-activated receptor \u03b3 agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats","volume":"124","author":"Kubo","year":"2014","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2018.03.001_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jphs.2017.08.004","article-title":"Effect of the antidiabetic agent pioglitazone on bone metabolism in rats","volume":"135","author":"Kanda","year":"2017","journal-title":"J\u00a0Pharmacol Sci"},{"key":"10.1016\/j.jphs.2018.03.001_bib6","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S1097-2765(00)80211-7","article-title":"PPAR \u03b3 is required for the differentiation of adipose tissue in\u00a0vivo and in\u00a0vitro","volume":"4","author":"Rosen","year":"1999","journal-title":"Mol Cell"},{"key":"10.1016\/j.jphs.2018.03.001_bib7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.2337\/diabetes.46.9.1393","article-title":"Pioglitazone induces in\u00a0vivo adipocyte differentiation in the obese Zucker fa\/fa rat","volume":"46","author":"Hallakou","year":"1997","journal-title":"Diabetes"},{"key":"10.1016\/j.jphs.2018.03.001_bib8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/13813455.2011.557386","article-title":"IRS2 and PTP1B: two opposite modulators of hepatic insulin signalling","volume":"117","author":"Valverde","year":"2011","journal-title":"Arch Physiol Biochem"},{"key":"10.1016\/j.jphs.2018.03.001_bib9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1677\/jme.1.01694","article-title":"Mechanism of protein tyrosine phosphatase 1B-mediated inhibition of leptin signalling","volume":"34","author":"Lund","year":"2005","journal-title":"J\u00a0Mol Endocrinol"},{"key":"10.1016\/j.jphs.2018.03.001_bib10","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1126\/science.283.5407.1544","article-title":"Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B","volume":"283","author":"Elchebly","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jphs.2018.03.001_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.molmet.2014.01.008","article-title":"Improved metabolic phenotype of hypothalamic PTP1B-deficiency is dependent upon the leptin receptor","volume":"3","author":"Tsou","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.jphs.2018.03.001_bib12","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/nrd895","article-title":"Protein tyrosine phosphatase 1B inhibitors for diabetes","volume":"1","author":"Johnson","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jphs.2018.03.001_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.4155\/fmc-2016-0064","article-title":"Recent advances in the development of protein tyrosine phosphatase 1B inhibitors for Type 2 diabetes","volume":"8","author":"Qian","year":"2016","journal-title":"Futur Med Chem"},{"key":"10.1016\/j.jphs.2018.03.001_bib14","doi-asserted-by":"crossref","first-page":"11357","DOI":"10.1073\/pnas.142298199","article-title":"PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice","volume":"99","author":"Zinker","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jphs.2018.03.001_bib15","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/sj.ijo.0801599","article-title":"A\u00a0spermine-coupled cholesterol metabolite from the shark with potent appetite suppressant and antidiabetic properties","volume":"25","author":"Zasloff","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.jphs.2018.03.001_bib16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/oby.2009.444","article-title":"Inhibition of PTP1B by trodusquemine (MSI-1436) causes fat-specific weight loss in diet-induced obese mice","volume":"18","author":"Lantz","year":"2010","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.jphs.2018.03.001_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/mol.104.005553","article-title":"Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms","volume":"67","author":"Erbe","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jphs.2018.03.001_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1463-1326.2009.01162.x","article-title":"Pharmacological profiles of a novel protein tyrosine phosphatase 1B inhibitor, JTT-551","volume":"12","author":"Fukuda","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jphs.2018.03.001_bib19","first-page":"680348","article-title":"Pharmacological effects of JTT-551, a novel protein tyrosine phosphatase 1B inhibitor, in diet-induced obesity mice","volume":"2014","author":"Ito","year":"2014","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jphs.2018.03.001_bib20","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1248\/cpb.c17-00635","article-title":"Novel non-carboxylate benzoylsulfonamide-based protein tyrosine phosphatase 1B inhibitors with non-competitive actions","volume":"65","author":"Morishita","year":"2017","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.jphs.2018.03.001_bib21","doi-asserted-by":"crossref","first-page":"24844","DOI":"10.1074\/jbc.M310688200","article-title":"Transgenic overexpression of protein-tyrosine phosphatase 1B in muscle causes insulin resistance, but overexpression with leukocyte antigen-related phosphatase does not additively impair insulin action","volume":"279","author":"Zabolotny","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jphs.2018.03.001_bib22","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/0026-0495(95)90012-8","article-title":"Increased abundance of specific skeletal muscle protein-tyrosine phosphatases in a genetic model of insulin-resistant obesity and diabetes mellitus","volume":"44","author":"Ahmad","year":"1995","journal-title":"Metabolism"},{"key":"10.1016\/j.jphs.2018.03.001_bib23","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2337\/db11-0744","article-title":"Skeletal muscle protein tyrosine phosphatase 1B regulates insulin sensitivity in African Americans","volume":"61","author":"Stull","year":"2012","journal-title":"Diabetes"},{"key":"10.1016\/j.jphs.2018.03.001_bib24","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1248\/cpb.c15-00508","article-title":"Novel 2,7-substituted (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor \u03b3 partial agonists with protein-tyrosine phosphatase 1B inhibition","volume":"63","author":"Otake","year":"2015","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.jphs.2018.03.001_bib25","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2174\/156802608786413474","article-title":"Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress","volume":"8","author":"Cho","year":"2008","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.jphs.2018.03.001_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/c543ef23-f1b1-4bc7-9593-32387653bc05","article-title":"Adipocyte-specific protein tyrosine phosphatase 1B deletion increases lipogenesis, adipocyte cell size and is a minor regulator of glucose homeostasis","volume":"7","author":"Owen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jphs.2018.03.001_bib27","doi-asserted-by":"crossref","first-page":"18318","DOI":"10.1074\/jbc.M908392199","article-title":"Overexpression of protein-tyrosine phosphatase-1B in adipocytes inhibits insulin-stimulated phosphoinositide 3-kinase activity without altering glucose transport or Akt\/Protein kinase B activation","volume":"275","author":"Venable","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jphs.2018.03.001_bib28","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2337\/diabetes.52.1.21","article-title":"Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob\/ob mice","volume":"52","author":"Gum","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.jphs.2018.03.001_bib29","doi-asserted-by":"crossref","first-page":"E1495","DOI":"10.1152\/ajpendo.00366.2013","article-title":"Divergent compensatory responses to high-fat diet between C57BL6\/J and C57BLKS\/J inbred mouse strains","volume":"305","author":"Sims","year":"2013","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jphs.2018.03.001_bib30","doi-asserted-by":"crossref","first-page":"E291","DOI":"10.1152\/ajpendo.90513.2008","article-title":"HF diets increase hypothalamic PTP1B and induce leptin resistance through both leptin-dependent and -independent mechanisms","volume":"296","author":"White","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.jphs.2018.03.001_bib31","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S1534-5807(02)00149-1","article-title":"Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B","volume":"2","author":"Cheng","year":"2002","journal-title":"Dev Cell"},{"key":"10.1016\/j.jphs.2018.03.001_bib32","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm1435","article-title":"Neuronal PTP1B regulates body weight, adiposity and leptin action","volume":"12","author":"Bence","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.jphs.2018.03.001_bib33","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.2337\/diabetes.51.8.2405","article-title":"Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis","volume":"51","author":"Rondinone","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jphs.2018.03.001_bib34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1053\/beem.2002.0223","article-title":"Peripheral metabolic actions of leptin","volume":"16","author":"Muoio","year":"2002","journal-title":"Best Pract Res Clin Endocrinol Metab"}],"container-title":["Journal of Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318300422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347861318300422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:58:21Z","timestamp":1761163101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347861318300422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1347861318300422"],"URL":"https:\/\/doi.org\/10.1016\/j.jphs.2018.03.001","relation":{},"ISSN":["1347-8613"],"issn-type":[{"value":"1347-8613","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic effects of the allosteric protein tyrosine phosphatase 1B inhibitor KY-226 on experimental diabetes and obesity via enhancements in insulin and leptin signaling in mice","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jphs.2018.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.","name":"copyright","label":"Copyright"}]}}